25 October 2017 - Starpharma today announced it has received Australian marketing approval from the TGA for VivaGel BV, which is intended for treatment of bacterial vaginosis. 

Launch plans for VivaGel BV are well advanced and the product is expected to be available in pharmacies in the New Year.

VivaGel BV, an Australian innovation, was developed by Starpharma and will be marketed in Australia by Aspen Pharmacare as Fleurstat BV gel, and will carry the VivaGel brand. Aspen is responsible for all marketing, promotion and local distribution of the product to clinicians and pharmacies. Starpharma will supply Aspen with the VivaGel BV product and will also receive royalties on net sales.

The TGA approval is significant not only for the Australian market but also internationally as there are many countries in Asia, the Middle East and South America where marketing approval is largely based on Starpharma’s home-country registration.

Read Starpharma press release